- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Fr | Pasithea Therapeutics Corp. - S-8, Securities to be offered to employees in employee benefit plans | 1 | SEC Filings | ||
| 13.01. | Pasithea Therapeutics Provides Outlook on PAS-004 Clinical Programs and Data Release Timelines | 110 | GlobeNewswire (Europe) | MIAMI, Jan. 13, 2026 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. (NASDAQ: KTTA) ("Pasithea" or the "Company"), a clinical-stage biotechnology company developing PAS-004, a next-generation oral... ► Artikel lesen | |
| 15.12.25 | Pasithea Therapeutics Corp. - 8-K, Current Report | - | SEC Filings | ||
| PASITHEA THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| 08.12.25 | Pasithea Therapeutics stock initiated with Buy rating at H.C. Wainwright | 2 | Investing.com | ||
| 02.12.25 | Pasithea Therapeutics Announces Closing of $60 Million Public Offering of Common Stock | 3 | GlobeNewswire (USA) | ||
| 28.11.25 | Pasithea Therapeutics Shares Surge Nearly 39% After $60 Mln Equity Raise | 1 | RTTNews | ||
| 28.11.25 | Pasithea Therapeutics Prices $60 Mln Public Offering To Advance MEK Inhibitor, Stock Up | 4 | RTTNews | ||
| 28.11.25 | Pasithea Therapeutics Announces Pricing of $60 Million Public Offering of Common Stock | 2 | GlobeNewswire (USA) | ||
| 26.11.25 | Pasithea Therapeutics Corp. - S-1/A, General form for registration of securities | 14 | SEC Filings | ||
| 25.11.25 | Pasithea Therapeutics Corp. - 8-K, Current Report | - | SEC Filings | ||
| 25.11.25 | ALS Association awards $1 million to study Pasithea's PAS-004 in ALS | 2 | Investing.com | ||
| 24.11.25 | Pasithea reports positive safety data from PAS-004 cancer trial | 7 | Investing.com | ||
| 21.11.25 | Pasithea reports positive PK data for PAS-004 tablet formulation | 1 | Investing.com | ||
| 21.11.25 | Pasithea Therapeutics Announces Positive PAS-004 Tablet Pharmacokinetic (PK) Data in Ongoing Phase 1/1b Trial in Adult NF1 Patients | 232 | GlobeNewswire (Europe) | -- Tablet PK exposure increases proportionally with an increase in dose -- -- More favorable PK properties in tablets enable a lower dose to achieve the same exposure as the capsule formulation, with... ► Artikel lesen | |
| 20.11.25 | Pasithea meldet positive Zwischendaten für MEK-Inhibitor in Krebsstudie | 5 | Investing.com Deutsch | ||
| 20.11.25 | Pasithea reports positive interim data for MEK inhibitor in cancer trial | 1 | Investing.com | ||
| 20.11.25 | Pasithea Therapeutics Announces Positive Phase 1 Data Including Partial Response, Demonstrating Monotherapy Clinical Activity and Favorable Safety Profile for PAS-004 in Advanced Cancer Study | 187 | GlobeNewswire (Europe) | -- Evidence of Monotherapy Activity: Partial response observed in a MEK-rechallenge 3rd-line melanoma patient with BRAF V600E mutation who remains on trial for more than 11 months -- -- A second MEK-rechallenge... ► Artikel lesen | |
| 18.11.25 | Pasithea Therapeutics Corp. - S-1, General form for registration of securities | - | SEC Filings | ||
| 13.11.25 | Pasithea Therapeutics Corp. - 10-Q, Quarterly Report | - | SEC Filings | ||
| 04.11.25 | Pasithea Therapeutics Announces Activation of Clinical Trial Site at University of Alabama at Birmingham for Ongoing Phase 1/1b Trial of PAS-004 in Adult NF1 Patients | 127 | GlobeNewswire (Europe) | MIAMI, Nov. 04, 2025 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. (Nasdaq: KTTA) ("Pasithea" or the "Company"), a clinical-stage biotechnology company developing PAS-004, a next-generation macrocyclic... ► Artikel lesen |
1 2 3 Weiter >>
42 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| OCUGEN | 1,218 | -0,69 % | Ocugen Announces Positive Preliminary Phase 2 Data from OCU410 Modifier Gene Therapy for Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration | Phase 2 (~50% of patients evaluated to date at 12 months) shows 46% lesion growth reduction vs. controlThere are no OCU410-related serious adverse events reported across the Phase 1 and Phase 2 clinical... ► Artikel lesen | |
| ABIVAX | 94,60 | -0,11 % | Abivax-Aktie: AstraZeneca soll Übernahmeversuch starten | Einem brandaktuellen Bericht der französischen Le Lettre zufolge prüft der britische Pharmariese AstraZeneca ein Übernahmeangebot für das französische Biotechunternehmen Abivax. Zuvor galt insbesondere... ► Artikel lesen | |
| ADAPTIVE BIOTECHNOLOGIES | 15,650 | +0,22 % | The Analyst Verdict: Adaptive Biotechnologies In The Eyes Of 4 Experts | ||
| GENPREX | 2,650 | +7,72 % | Genprex, Inc.: Genprex Provides Clinical Update on Diabetes Gene Therapy Program | Company Achieves Clinical Development Milestones in 2025, Advances Program for Future Scale Up and Studies
AUSTIN, Texas, Jan. 7, 2026 /PRNewswire/ -- Genprex,... ► Artikel lesen | |
| REZOLUTE | 2,740 | -2,84 % | Rezolute, Inc.: Rezolute Provides Insights from its Phase 3 sunRIZE Study in Congenital Hyperinsulinism and Shares Findings from its Expanded Access Program in Tumor Hyperinsulinism | Company believes that data from sunRIZE and the Expanded Access Program (EAP) provide evidence of activity of ersodetug in both indications Company plans to meet with FDA to align on path forward... ► Artikel lesen | |
| SPRUCE BIOSCIENCES | 77,00 | -3,58 % | Harbour BioMed Acquires Common Stock in Spruce Biosciences, Deepening Strategic Collaboration | CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SHANGHAI, Jan. 18, 2026 /PRNewswire/ -- Harbour BioMed (HKEX: 02142), a global biopharmaceutical company committed to... ► Artikel lesen | |
| GALECTO | 26,280 | +4,70 % | Galecto, Inc.: Galecto Announces Acquisition of Damora Therapeutics | Acquisition of Damora and concurrent oversubscribed $285 million private investment positions the company to advance potentially best-in-class portfolio to improve outcomes in patients with Myeloproliferative... ► Artikel lesen | |
| UNICYCIVE THERAPEUTICS | 5,965 | -10,57 % | Unicycive Therapeutics, Inc.: Unicycive Therapeutics Announces FDA Acceptance of Oxylanthanum Carbonate (OLC) New Drug Application (NDA) Resubmission | DA assigns Prescription Drug User Fee Act (PDUFA) target date of June 27, 2026Ended 2025 with unaudited cash position of $41.3M with expected runway into 2027 LOS ALTOS, Calif., Jan. 29, 2026 (GLOBE... ► Artikel lesen | |
| FIBROBIOLOGICS | 0,266 | -5,67 % | After-Hours Biotech Rally: FBLG, NYXH, FBIO, RVTY, OPCH, ATNM, DSGN Climb On Earnings And Momentum | BRUSSELS/FRANKFURT/PARIS (dpa-AFX) - Several biotech and healthcare names posted notable gains in Monday's after-hours trading session, with moves driven by earnings updates, guidance announcements... ► Artikel lesen | |
| QIAGEN | 44,620 | +0,64 % | Adidas schmiert ab, Qiagen zieht an: DAX-Ausblick | Der DAX hat eine volatile Woche hinter sich. Unter dem Strich büßte das größte deutsche Börsenbarometer knapp 400 Punkte ein und schloss -1,57% tiefer mit 24.900 Punkten. Die höchsten Verluste gab es... ► Artikel lesen | |
| PRAXIS PRECISION MEDICINES | 314,30 | -0,12 % | H.C. Wainwright raises Praxis Precision Medicines stock price target to $1,245 | ||
| NUVALENT | 102,89 | +0,45 % | Royalty Pharma plc: Royalty Pharma Acquires Royalty Interest in Nuvalent's Neladalkib and Zidesamtinib for Up to $315 Million | NEW YORK, Dec. 16, 2025 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it has acquired a pre-existing royalty interest in Nuvalent's neladalkib and zidesamtinib from an... ► Artikel lesen | |
| NURIX THERAPEUTICS | 16,520 | -6,03 % | Nurix Therapeutics, Inc.: Nurix Therapeutics Reports Fourth Quarter and Fiscal Year 2025 Financial Results and Provides a Corporate Update | First patients dosed in DAYBreak registrational program for bexobrutideg in relapsed/refractory CLLPresented Phase 1 results at ASH 2025 that support bexobrutideg's potential best-in-class profile... ► Artikel lesen | |
| AMYLYX PHARMACEUTICALS | 14,290 | -3,77 % | Gubra A/S: Amylyx Pharmaceuticals Announces Nomination of AMX0318 as a Novel, Long-Acting GLP-1 Receptor Antagonist Development Candidate, Identified in Collaboration with Gubra | AMX0318 selected as development candidate after meeting key criteria, demonstrating a robust chemical stability profile, strong in vitro potency, evidence of in vivo efficacy and tolerability, high... ► Artikel lesen | |
| OLEMA PHARMACEUTICALS | 25,720 | -1,30 % | Olema Oncology Announces Departure of Chief Operating and Financial Officer | SAN FRANCISCO, Jan. 30, 2026 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. ("Olema", or "Olema Oncology", Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development... ► Artikel lesen |
PASITHEA THERAPEUTICS CORP gehört der Branche Biotechnologie an. Mit einer aktuellen Kursveränderung von 0,000 (0,00 %) liegt der Kurs bei 0,860 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu PASITHEA THERAPEUTICS CORP finden Sie auf Wallstreet Online.